CDC Guidelines for Ivermectin Treatment of Scabies

Dosing and Regimen

• For an adult weighing approximately 140 kg, administer oral ivermectin 200 µg/kg (≈ 30 mg, rounded from 28.4 mg) with food on day 0 and repeat the same dose on day 14. 1
• A second dose on day 14 is mandatory because ivermectin has limited ovicidal activity; a single dose results in markedly higher treatment failure. 2, 3

Administration

• Ivermectin should be taken with a substantial meal (preferably high‑fat) to increase bioavailability about 2.5‑fold; taking it on an empty stomach reduces absorption by roughly 60 %. 2, 1

Special Population Considerations

• No dose adjustment is required for patients with renal impairment, regardless of creatinine clearance. 2, 3
• In patients with severe liver disease, the safety of repeated dosing is uncertain; clinicians should use caution or consider alternative therapy. 2, 3
• Although one study suggested increased mortality in frail elderly patients, later research has not confirmed this; close monitoring of vulnerable older adults is advised. 1, 4

Post‑Treatment Management

• Pruritus and rash may persist for up to 2 weeks after successful therapy due to inflammatory response to dead mites; this does not indicate treatment failure. 2, 3
• Re‑evaluate patients 2–4 weeks after the second dose; persistent symptoms beyond 2 weeks or detection of live mites warrants assessment for treatment failure, reinfection, or resistance. 2, 3

Environmental and Contact Measures

• All bedding and clothing should be machine‑washed and machine‑dried on hot cycles (or dry‑cleaned) to eradicate mites. 2, 4
• Items that cannot be washed must be removed from body contact for at least 72 hours, as mites cannot survive off the human host beyond this period. 2, 4
• All household and sexual contacts within the preceding month must receive the same two‑dose ivermectin regimen, even if asymptomatic, to prevent reinfection. 3

Common Pitfalls to Avoid

• Avoid prescribing a single dose, which is the leading cause of treatment failure and may promote resistance. 3
• Do not advise patients to take ivermectin on an empty stomach, as this markedly reduces drug absorption. 2, 1
• Do not interpret persistent symptoms at 1 week as treatment failure; allow the full 2–4 week inflammatory period before considering retreatment. 2, 3
• Do not treat the patient in isolation; simultaneous treatment of contacts is essential to prevent apparent failure due to reinfection. 3

Crusted (Norwegian) Scabies

• The standard 200 µg/kg regimen on days 0 and 14 is insufficient for crusted scabies; an intensified schedule of ivermectin 200 µg/kg on days 1, 2, 8, 9, and 15 combined with daily topical permethrin is recommended. 2, 3
• Crusted scabies occurs in immunocompromised individuals (e.g., HIV infection, organ transplantation, systemic corticosteroid therapy, hematologic malignancies) and warrants specialist consultation. 2, 3

CDC Recommendations for Ivermectin Treatment of Scabies

Dosing and Administration

• Oral ivermectin 200 µg/kg (≈14 mg for a 72 kg adult) should be given on day 0 and repeated on day 14, taken with food to maximize absorption. The food‑taken dose increases bioavailability about 2.5‑fold, enhancing epidermal drug penetration. 5, 6, 7, 8
• Weight conversion for dosing: 159 lb ≈ 72 kg. 9

Rationale for Two‑Dose Regimen

• A second dose at 2 weeks is required because ivermectin has limited ovicidal activity; without it, treatment failure rates rise sharply. 5, 6, 8

Environmental and Contact Measures

• All bedding and clothing should be machine‑washed and machine‑dried on hot cycles (or dry‑cleaned) to eliminate mites. 5, 6, 10
• If washing is not feasible, items should be removed from body contact for at least 72 hours to reduce transmission risk. 5, 6, 10
• All household contacts, even if asymptomatic, must receive the same ivermectin regimen simultaneously to prevent reinfestation. 5, 7

Safety Considerations

• Renal impairment does not require dose adjustment of ivermectin. 6, 8
• Pregnancy is classified as low‑risk based on available human data. 5, 7, 11
• One study reported increased mortality among elderly, debilitated patients, but subsequent reports have not confirmed this finding. 6, 7, 8

Post‑Treatment Management

• Persistent pruritus for up to 2 weeks after therapy does not indicate treatment failure; it reflects ongoing inflammatory response. Symptom relief can be provided with topical corticosteroids and oral antihistamines. 6, 8, 12, 9

Reassessment Guidelines

• Patients should be re‑evaluated 2–4 weeks after the final dose. If symptoms persist beyond 2 weeks, consider possible drug resistance, reinfection from untreated contacts or fomites, or the need for alternative therapy. 8, 6, 12

Special Populations

• Crusted (Norwegian) scabies requires an intensified schedule: ivermectin 200 µg/kg on days 1, 2, 8, 9, and 15 combined with daily topical permethrin. This regimen is not indicated for typical scabies presentations. 5, 6, 8

CDC Guidelines for Ivermectin Use in Scabies Management

Initial Treatment Recommendations

• The Centers for Disease Control and Prevention (CDC) recommends the intensive oral ivermectin schedule 200 µg/kg on days 1, 2, 8, 9, 15, and 25 only for crusted (Norwegian) scabies, not for uncomplicated disease. 13
• For uncomplicated scabies, the CDC advises a two‑dose regimen of ivermectin 200 µg/kg on day 0 and a repeat dose on day 14; the second dose is required because ivermectin has limited ovicidal activity and cannot eradicate eggs present at the first administration. 13

Retreatment Protocol

• If crusted scabies is confirmed (e.g., extensive hyperkeratotic lesions, immunocompromise, or very high mite burden), the same intensive regimen (days 1, 2, 8, 9, 15, 25) should be repeated. 13
• In cases of recurrence of uncomplicated scabies, the standard two‑dose schedule (day 0 and day 14) is sufficient; no additional intensive dosing is needed. 13

Causes of Apparent Treatment Failure

• Omission of the mandatory second dose on day 14 in the standard regimen markedly increases failure rates because eggs are not killed. This is highlighted by CDC data. 13

Safety Considerations

• A CDC‑cited analysis noted an initial signal of increased mortality among frail elderly patients receiving repeated ivermectin, but subsequent studies have not confirmed this; therefore, close monitoring of vulnerable older adults is recommended. 13

Alternative and Combination Therapies

• The CDC recommends combining topical permethrin 5 % cream with oral ivermectin for crusted scabies and suggests this combination may be considered for refractory cases of any scabies type. 13

Emerging Ivermectin Resistance

• Reports from the journal Infectious Diseases of Poverty indicate that ivermectin resistance has emerged in isolated regions, although it remains rare; persistent infestation despite optimal adherence to CDC‑recommended regimens should raise suspicion for resistance. 14

Post‑Treatment Follow‑up

• The CDC advises re‑evaluation of patients 2–4 weeks after the final ivermectin dose; ongoing symptoms beyond 2 weeks or detection of live mites warrants assessment for true treatment failure, reinfestation, or possible resistance. 13